Dengvaxia (CYD-TDV), first dengue vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule invented by Sanofi Pasteur. CYD-TDV and DENVax are expected to lose market share to the domestically-produced live-attenuated vaccine, TV-003 due to its lower price. Today dengue resides in 125 countries around the world and Aedes aegypti, the primary vector is everywhere, making transmission reduction is the major area of concern.
According to WHO, number of deaths caused by dengue virus was 297, 873 in 2012 and 159 per million in low income, lower-middle income and upper-middle income regions. The global market for dengue vaccines holds the opportunities for drug makers when the will be able to successfully develop effective vaccines for all age group. The major growth driver of global dengue vaccine market is the process of urbanization.
Merger & acquisition is the key strategy for the vendors of dengue market, for instance, Sanofi Be a Wall against Dengue disease education campaign to raise awareness on dengue prevention in Singapore, launched under partnership of Pasteur and Ya Kun Kaya Toast in conjunction with ASEAN Dengue Day (15 June 2017). Similarly, Takeda pharmaceutical company and Biological E. limited entered into a partnership for the development and delivery of low-cost combination vaccines. There are 5 vaccines in Phase I-III and 4 first-in-class vaccines in pipeline assessment.
Inquire for Sample Copy of This Report at: https://www.marketinsightsreports.com/reports/120484822/global-dengue-vaccine-market-outlook-2024-global-opportunity-and-demand-analysis-market-forecast-2016-2024/inquiry
These are Manufacturers For Dengue Vaccine Market: Sanofi Pasteur, Synopsis, Business Strategy, Product Portfolio, SWOT Analysis, Biological E. Limited, Merck & Co, Glaxosmithkline, Pfizer , Panacea Biotech Ltd, Vabiotech, Butantan Institute, etc.
Global Dengue Vaccine Market is categorized on the following basis:
By Technology :
o Live attenuated vaccine
o Chimeric Live attenuated vaccine
o Subunit vaccine
o Inactivated vaccine
o Nucleic acid based vaccine
By End Users :
o Diagnostic Labs
o Government Institutes
o Others (retail pharmacies, online pharmacies, etc)
Geographically, this report is segmented into several key Regions, with Sales, Sales, revenue, Market Share (%) and Growth Rate (%) of product in these regions, from 2012 to 2025 (forecast), covering United States, North America (Canada and Mexico), Latin America (Argentina, Mexico, Brazil and Rest of Latin America), Europe (Germany, Italy, Spain, France, The U.K., Netherlands, Sweden, Hungary, Russia, Poland, Rest of Europe), Asia-Pacific (China, India, Singapore, Japan, Hong-Kong, Australia, New Zealand, South Korea and Rest of Asia Pacific), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa), RoW (Rest of World).
Market Size and Forecast:
Global dengue vaccine market valued USD 0.22 billion in 2016 and is expected to reach USD 1.15 by 2024 at a CAGR of 17% over the forecast period.
Government Institutes dominate the global dengue vaccine market, accounting 45% market share in 2017 and is expected to account for 52% global dengue vaccine market share by 2024 followed by hospitals, diagnostic labs and NGO’s.
Geographically, more than 70% of global dengue vaccine revenue was emanated from APAC in 2016. Countries like Brazil, Mexico, Thailand, Singapore and India are the leading market for dengue vaccine. In America, around 500 million people are at the risk of getting dengue.
Growth Drivers and Challenges:
The key driving factors of global dengue market are increasing dengue fever occurrence, promising end stage vaccine pipeline, local production of dengue vaccines and innovation of live attenuated tetravalent dengue vaccine. However, less number of skilled professionals and unavailability of optimum diagnostic systems where dengue fever is visualized as a common febrile disease have driven the global dengue vaccine market.
Unplanned and uncontrolled urbanization, stiff competition among existing players, high possibilities of side effects, lack of basic amenities in communities, poor environmental management, and climatic change hinders the global dengue vaccine market. In addition, supply side infrastructure bottlenecks such as surveillance system, standardized diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the restraints responsible for the decline of global dengue vaccine market.
MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
+1 (704) 266-3234 | firstname.lastname@example.org
Connect With us on: